NASDAQ:QNRX Quoin Pharmaceuticals (QNRX) Stock Price, News & Analysis $3.90 -0.13 (-3.23%) Closing price 03:59 PM EasternExtended Trading$4.00 +0.10 (+2.56%) As of 06:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC Filings About Quoin Pharmaceuticals Stock (NASDAQ:QNRX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Quoin Pharmaceuticals alerts:Sign Up Key Stats Today's Range$3.90▼$4.1150-Day Range$3.90▼$7.8752-Week Range$3.25▼$23.50Volume31,730 shsAverage Volume50,456 shsMarket Capitalization$18.72 millionP/E RatioN/ADividend YieldN/APrice Target$17.00Consensus RatingModerate Buy Company Overview Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) is a clinical-stage specialty pharmaceutical company focused on developing treatments for rare diseases with significant unmet medical needs. The company’s programs are primarily designed to address disorders affecting the skin and other tissues, with an emphasis on topical drug-delivery technologies. Quoin’s lead product candidate, QRX003, is an investigational topical lotion being developed for Netherton syndrome, a rare genetic skin disorder associated with impaired skin barrier function and inflammation. The company is also developing QRX004, an investigational topical treatment for recessive dystrophic epidermolysis bullosa, a rare inherited disorder that causes fragile skin and blistering. Quoin Pharmaceuticals is headquartered in the United States and operates as an international biotechnology company serving the rare-disease treatment market. The company was formerly known as Cellect Biotechnology Ltd. and adopted the Quoin Pharmaceuticals name as it shifted its focus toward rare-disease therapeutics. Michael Myers serves as the company’s chief executive officer.AI Generated. May Contain Errors. Read More Quoin Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks84th Percentile Overall ScoreQNRX MarketRank™: 4.184018740235 of 5 starsQuoin Pharmaceuticals scored higher than 84% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.9 / 5Analyst RatingModerate Buy Consensus RatingQuoin Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 3 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialQuoin Pharmaceuticals has a consensus price target of $17.00, representing about 335.9% upside from its current price of $3.90.Amount of Analyst CoverageQuoin Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.Read more about Quoin Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Book Value per Share RatioQuoin Pharmaceuticals has a P/B Ratio of 0.25. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Quoin Pharmaceuticals' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.67% of the float of Quoin Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverQuoin Pharmaceuticals has a short interest ratio ("days to cover") of 1.38, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Quoin Pharmaceuticals has recently decreased by 48.16%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldQuoin Pharmaceuticals does not currently pay a dividend.Dividend GrowthQuoin Pharmaceuticals does not have a long track record of dividend growth. News and Social Media2.3 / 5News Sentiment0.74 News SentimentQuoin Pharmaceuticals has a news sentiment score of 0.74. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Quoin Pharmaceuticals this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for QNRX on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days. Company Ownership3.9 / 5Insider TradingAcquiring Shares Cluster Insider Buying4 insiders have purchased shares of Quoin Pharmaceuticals in the last three months. Multiple insiders buying is a strong bullish signal.Net Insider BuyingOver the last three months, insiders have purchased a net $279,966.00 in company stock, which represents 1.4955% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Quoin Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $279,966.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders7.54% of the stock of Quoin Pharmaceuticals is held by insiders.Percentage Held by Institutions8.63% of the stock of Quoin Pharmaceuticals is held by institutions.Read more about Quoin Pharmaceuticals' insider trading history. Receive QNRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Quoin Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. QNRX Stock News HeadlinesQuoin Secures EMA Orphan Drug Designation For QRX003 In Rare Skin DisorderOctober 14 at 1:47 PM | rttnews.comQuoin Pharmaceuticals Announces European Medicines Agency (EMA) Grants Orphan Drug Designation for QRX003 for the Treatment of Peeling Skin SyndromeOctober 14 at 6:30 AM | globenewswire.comTrump’s issues shocking Executive Order on U.S. DollarThree days into his second term, President Trump signed Executive Order 14178 a move the press barely covered. Buried inside is what some call the legal groundwork for the biggest change to American money in over a century, with a key Treasury vote potentially as soon as January 18. Ian King, Chief Strategist at Strategic Fortunes, breaks down what the order could mean for the dollar and the financial system.October 16 at 1:00 AM | Banyan Hill Publishing (Ad)BTIG Research Begins Coverage on Quoin Pharmaceuticals (NASDAQ:QNRX)October 13 at 6:02 AM | americanbankingnews.comQuoin Pharmaceuticals Announces Acceptance of QRX003 Paper in Dermatology and TherapyOctober 6, 2026 | globenewswire.comFour Small-Cap Stocks to Watch With Small Floats and Big Catalysts (CHGA, QNRX, MYSE, LNKS)September 25, 2026 | marketscreener.comMQuoin Gets FDA Fast Track Designation For QRX003 In Peeling Skin SyndromeSeptember 23, 2026 | rttnews.comQuoin Pharmaceuticals, Inc.: Quoin Pharmaceuticals Announces FDA Fast Track Designation for QRX003 for the Treatment of Peeling Skin SyndromeSeptember 22, 2026 | finanznachrichten.deSee More Headlines QNRX Stock Analysis - Frequently Asked Questions How have QNRX shares performed this year? Quoin Pharmaceuticals' stock was trading at $14.43 at the beginning of the year. Since then, QNRX shares have decreased by 73.0% and is now trading at $3.90. How were Quoin Pharmaceuticals' earnings last quarter? Quoin Pharmaceuticals, Ltd. Sponsored ADR (NASDAQ:QNRX) issued its quarterly earnings data on Friday, August, 14th. The company reported ($1.90) EPS for the quarter, missing analysts' consensus estimates of ($1.61) by $0.29. When did Quoin Pharmaceuticals' stock split? Quoin Pharmaceuticals shares reverse split on the morning of Monday, July 17th 2023.The 1-12 reverse split was announced on Monday, July 17th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, July 17th 2023. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split. When did Quoin Pharmaceuticals IPO? Quoin Pharmaceuticals (QNRX) raised $0 in an initial public offering (IPO) on Friday, July 29th 2016. The company issued 1,292,308 shares at a price of $0.00 per share. How do I buy shares of Quoin Pharmaceuticals? Shares of QNRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Quoin Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Quoin Pharmaceuticals investors own include Rivian Automotive (RIVN), AMC Entertainment (AMC), NIO (NIO), Pfizer (PFE), SNDL (SNDL), Tesla (TSLA) and Advanced Micro Devices (AMD). Company Calendar Last Earnings8/14/2026Today10/16/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (3d) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 As of 3 days ago, QNRX's financial health entered the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:QNRX CIK1671502 Webquoinpharma.com Phone+97299741444Fax972-9767-8750Employees6Year FoundedN/APrice Target and Rating Average Price Target for Quoin Pharmaceuticals$17.00 High Price Target$20.00 Low Price Target$14.00 Potential Upside/Downside+335.9%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($25.18) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$15.81 million Net MarginsN/A Pretax MarginN/A Return on Equity-489.57% Return on Assets-221.17% Debt Debt-to-Equity RatioN/A Current Ratio1.76 Quick Ratio1.76 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$15.64 per share Price / Book0.25Miscellaneous Outstanding Shares4,800,000Free Float4,442,000Market Cap$18.72 million OptionableNot Optionable Beta1.56 The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:QNRX) was last updated on 10/16/2026 by MarketBeat.com Staff. From Our PartnersElon Musk’s 4th Wealth Window Set to Open by October 30Jeff Brown, the analyst who flagged Bitcoin, Tesla, and Nvidia early, is tracking Elon Musk's next move. He po...Brownstone Research | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...Weiss Ratings | SponsoredSpaceX minted 4400 millionaires in a single daySpaceX minted 4,400 millionaires in a single day, and Tesla has turned more than 5,000 employees into milliona...Behind the Markets | SponsoredTrump’s issues shocking Executive Order on U.S. DollarThree days into his second term, President Trump signed Executive Order 14178 a move the press barely covered....Banyan Hill Publishing | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredA new income category is drawing serious money - here's whyForbes recently called a new category of exchange-traded income funds a 'golden era,' and Bloomberg noted the ...Investors Alley | SponsoredThe oil check Munger called his best dealCharlie Munger's $1,000 oil investment in 1962 later paid about $70,000 a year, totaling roughly $1 million ov...The Oxford Club | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Quoin Pharmaceuticals, Ltd. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Quoin Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
